Secondary package configured to holding a device for administration of a drug and / or preventing an inductive

By using 3A molecular sieve and active polymer components in the secondary packaging, combined with the hinge structure design, the problem of accidental opening of the secondary packaging is solved, ensuring the safe sealing and long-term use of the agent.

CN119032052APending Publication Date: 2024-11-26CSP TECHNOLOGIES INC
View PDF 0 Cites 2 Cited by

Patent Information

Application Number
CN202380033494.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-02-09
Filing Date
2023-06-29
Publication Date
2024-11-26

AI Technical Summary

Technical Problem

Secondary packaging may open accidentally during storage and transportation, resulting in exposure of the drug to the external environment, causing waste or damage, especially when the drug is expensive or difficult to obtain.

Method used

A specific type of desiccant formulation, such as 3A molecular sieve, is used to reduce pressure in the secondary packaging, thereby preventing the cap from accidentally opening and ensuring a safe seal of the agent administration device through the design of active polymer assembly and hinge structure.

Benefits of technology

It effectively reduces the possibility of accidental opening of secondary packaging, ensures the safety and sealing of the agent, extends the service life of the drug, and reduces pressure accumulation in high temperature environments.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN119032052A_ABST
    Figure CN119032052A_ABST
Patent Text Reader

Abstract

A secondary package configured to prevent accidental actuation of a device for administering a medicament includes a body defining a cavity for at least partially surrounding the device for administering the medicament. The active polymer component may optionally be located within the interior compartment of the secondary package. The active polymer component may include a mixture of a 3A molecular sieve, a base polymer, and optionally a channel former.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] CROSS-REFERENCE TO RELATED APPLICATIONS

[0002] This application claims priority to U.S. Provisional Application No. 63 / 484,097, filed on February 9, 2023, entitled “SECONDARY PACKAGING CONFIGURED TO HOLD AND / OR PREVENT INADVERTENT ACTUATION OF A DEVICE FOR ADMINISTERING MEDICINE OR A DRUG” and U.S. Provisional Application No. 63 / 367,753, filed on July 6, 2022, entitled “PACKAGING CONFIGURED TO PREVENT INADVERTENT ACTUATION OF A DEVICE DESIGN TO ADMINISTER MEDICINE OR ADRUG”, each of which is incorporated herein by reference in its entirety. Technical Field

[0003] The technology of the present disclosure generally relates to packaging, which is configured to hold a device designed to administer a content (such as but not limited to a drug) or prevent accidental opening and / or actuation of the device. More specifically, in an optional embodiment, the technology of the present disclosure relates to a secondary packaging, which is configured to hold an inhaler therein or prevent accidental opening and / or actuation thereof. Background Art

[0004] Devices for administering or releasing contents such as drugs are often stored or shipped in secondary packaging that protects the device and can be discarded or reused once the device is removed from the secondary packaging for use by, for example, an end user or healthcare professional.

[0005] The secondary packaging may contain a desiccant plug located within the secondary packaging, as disclosed in US Patent No. 10,765, 602. The desiccant may preserve or extend the useful life of the drug within the device.

[0006] The secondary packaging may be accidentally opened from time to time and / or in certain circumstances or uses. Accidental opening of the secondary packaging may expose the device therein to the external environment unnecessarily or undesirably. Such exposure risks wasting or degrading the contents of the device (e.g., in the case of a drug in a delivery device that degrades in the presence of moisture) or damaging or misplacing the device. This is particularly problematic when the drug is expensive or difficult to obtain, or when it may be difficult for the user to quickly or reliably obtain the replacement drug needed to treat a critical medical situation. Summary of the invention

[0007] To overcome the above-referenced and other shortcomings of the prior art, Applicants have researched and identified various ways to prevent accidental opening of secondary packaging.

[0008] Applicants have unexpectedly discovered that certain desiccant formulations used within secondary packaging may cause the closure on the package to open accidentally. Specifically, Applicants have discovered that some desiccant formulations may create an increased or enhanced internal pressure within a closed secondary packaging. This increased pressure may cause or contribute to the accidental opening of the closure on the secondary packaging.

[0009] Thus, Applicants have unexpectedly discovered that the use of a particular type of desiccant formulation can reduce or help reduce the pressure generated within a closed secondary package, thereby preventing or at least reducing the likelihood of accidental opening of a closure on the secondary package.

[0010] An object of an optional embodiment of the technology disclosed herein is to provide a cap and container assembly that provides a safe and sealed enclosure for a medication administration device therein while also including components that prevent premature discharge of medication and / or prevent opening of the cap relative to the container assembly.

[0011] It is another object of an optional embodiment of the presently disclosed technology to provide a drug delivery system that houses or accommodates a drug administration device in a manner that the drug administration device can be easily and quickly removed from a container for use. BRIEF DESCRIPTION OF THE DRAWINGS

[0012] The following detailed description of the technology of the present disclosure will be better understood when read in conjunction with the accompanying drawings, in which like reference numerals represent like elements throughout. To illustrate the technology of the present disclosure, various illustrative embodiments are shown in the drawings. However, it should be understood that the technology of the present disclosure is not limited to the precise arrangements and tools shown. In the drawings:

[0013] Figure 1 is a perspective view of a secondary package according to an optional aspect of the disclosed technology, with the lid shown in a closed position;

[0014] Figure 2 yes Figure 1 a perspective view of a secondary package of with the cover shown in an open position and a portion of a device for administering the contents therein exposed;

[0015] Figure 3 is along Figure 1 a cross-sectional perspective view of the secondary package taken along line II of FIG. 1 , wherein a portion of the device is shown in cross section within the cavity of the secondary package;

[0016] Figure 4 is along Figure 1 A cross-sectional perspective view of the secondary package taken along line II-II of FIG. 1 , wherein a portion of the device is shown in cross section in the cavity of the secondary package;

[0017] Figure 5 is a graph showing the volume of gas released during exposure at 50° C. as a function of time according to the technology of the present disclosure;

[0018] Figure 6 is a graph showing the evolution of pressure over time within the headspace of a secondary package of the disclosed technology;

[0019] Figure 7 is a perspective view of a secondary package according to an optional aspect of the disclosed technology, with the lid shown in an open position;

[0020] Figure 8 yes Figure 7 A top plan view of the secondary packaging;

[0021] Fig.9A yes Figure 7 a side elevation view of a secondary package of with the lid shown in a closed position;

[0022] Fig. 9B yes Fig.9A an enlarged view of detail "A";

[0023] Fig.10 yes Figure 7 an enlarged view of a portion of a secondary packaging;

[0024] Fig.11 yes Figure 7 an enlarged view of a portion of the secondary packaging; and

[0025] Fig.12 yes Figure 7 An enlarged view of a portion of the secondary packaging. DETAILED DESCRIPTION

[0026] Although systems, devices and methods are described herein by way of examples and embodiments, those skilled in the art recognize that the technology of the present disclosure is not limited to the described embodiments or drawings. In fact, the technology of the present disclosure encompasses all modifications, equivalents and alternatives that fall within the spirit and scope of the appended claims. The features of any one embodiment disclosed herein may be omitted or incorporated into another embodiment.

[0027] Any headings used herein are for organizational purposes only and are not intended to limit the scope of the specification or claims. As used herein, the word "may" is used in a permissive sense (i.e., a potential sense) rather than a mandatory sense (i.e., a necessary sense). Unless specifically set forth herein, the terms "a / an / a kind of" and "the" are not limited to one element, but should be understood to mean "at least one". The terms include the above-mentioned words, their derivatives, and words of similar meaning.

[0028] As used herein, "and / or" means referring to either or both of the items separated by such terms. For example, the phrase "A and / or B" will mean only A, only B, or both A and B.

[0029] As used herein, "generally" means "in a normal manner" as one of ordinary skill in the art would understand in connection with the modified term.

[0030] Directional phrases used herein, such as but not limited to top, bottom, left, right, upper, lower, front, rear and derivatives thereof, refer to the orientation of elements shown in the drawings and do not limit the claims unless explicitly stated therein.

[0031] In general, as used herein, the term "moisture resistant" is defined as moisture ingress (after three days) of less than 1500 μg of water, in another embodiment, less than 500 μg of water, in another embodiment, less than 300 μg of water, and in yet another embodiment, less than 150 μg of water, as determined by the following test method: (a) placing one gram plus or minus 0.25 grams of molecular sieve in a container and recording the weight; (b) completely closing the container; (c) placing the sealed container in an environmental chamber at 80% relative humidity and 72°F; (d) after one day, weighing the container containing the molecular sieve; (e) after four days, weighing the container containing the molecular sieve; and (f) subtracting the first day sample from the fourth day sample to calculate the moisture ingress of the container in micrograms of water. The preferred rate of ingress of moisture into a moisture resistant sealed container produced according to an aspect of the disclosed concept is in the range of about 200-300 μg of water or less per day. Thus, a "moisture resistant" seal is a sealing joint that, alone or in combination with additional sealing joints, helps to make the container "moisture resistant" according to the above definition.

[0032] The term "moisture resistant" is further discussed and / or defined in U.S. Patent Nos. 11,192,698 and 11,325,771 and U.S. Patent Application Publication No. 2021 / 0008771, each of which is incorporated herein by reference. For example, U.S. Patent No. 11,192,698 (e.g., see Figure 1 , 2 , 7 and 9) disclose an elastic seal, optionally in the form of an annular ring, on the inner surface of the cover. This seal can be configured to engage at least a portion of the body when the cover is in a closed position to form a supplementary moisture-proof seal between the cover and the body. This feature can optionally form at least one aspect of the technology disclosed herein.

[0033] As used herein, the term "resealable" means that the closure of the container can be opened or reopened and closed or reclosed many times (eg, more than 10 times) and still maintain its moisture barrier.

[0034] As used herein, the term "secondary" in the phrase "secondary packaging" means that the packaging is not intended to directly contain or hold contents that are consumed by a user, but is intended to hold a packaging or drug delivery device that directly contains or holds contents that are consumed by a user.

[0035] Referring now to the drawings in detail, wherein like reference numerals refer to like parts throughout, Figure 1-4 A secondary package, generally designated 10, and at least one device, such as a medication administration device, generally designated 12 is shown. Each device 12 can be configured to store, release and / or administer a content therein, such as, but not limited to, a drug. The secondary package 10 can be configured to hold or contain one or more devices 12 therein and prevent accidental actuation of the devices 12.

[0036] Optionally, device 12 is an inhaler, such as, but not limited to, a nasal drug delivery device, a nasal inhaler, a metered dose inhaler (MDI), a dry powder inhaler (DPI), and a soft mist inhaler (SMI). Device 12 can be any of a variety of medicament administration devices and medicaments.

[0037] The device 12 may optionally include a spring to facilitate movement (e.g., expansion and contraction) of the device 12 from an activated position in which at least some of the contents of the device 12 are released or administered to an inactivated position in which the contents of the device 12 are prevented from exiting. However, the device 12 is not limited to an inhaler, as the device 12 may be any structure configured to store, release, and / or administer the contents held therein, such as an eye dropper or a pepper spray.

[0038] In an optional embodiment, the device 12 may employ a so-called AMORPHOXTM The platform is used as a carrier for nasal drug delivery and is validated for both small and large molecules. AMORPHOX TM It can also act as a carrier of enzymes and spike proteins (including Sars-Cov2).

[0039] Optionally, the active pharmaceutical ingredient (API) stored in and / or delivered by the device 12 can be one or more of the following: naloxone, ketamine, midazolam, fentanyl, lorazepam, glucagon, nalmefene, epinephrine, apomorphine, cetrorelix, loxapine, eletriptan, ketorolac and / or olanzapine.

[0040] Optionally, device 12 may be used to store and / or deliver insulin and / or epinephrine and / or pharmaceutical agents to treat or alleviate symptoms of, for example, diabetes or asthma.

[0041] Device 12 may be pre-filled and provide a medicament in a dosage form. Specifically, device 12 may be a dispersing device that delivers a medicament in a dispersed form, such as in a metered aerosol or spray device. Device 12 may be pre-filled with a medicament in a final dosage form. Embodiments include, for example, devices such as those mentioned in 68 Federal Registers 36,675, 36,676, and 36,680 (June 18, 2003). Exemplary embodiments include intranasal aerosol and spray devices.

[0042] The secondary package 10 is particularly suitable for use with a device 10 for administering a powdered medicament (e.g., a powder for intranasal delivery). The medicament can be any medicament that can be delivered by a dispensing device. The medicament can be associated with one or more other ingredients, such as, for example, mentioned at 21 CFR §314.3.

[0043] In an optional embodiment, the medicament stored in the device 12 is a powdered medicament, such as glucagon. The device 12 can be configured to deliver glucagon or another medicament in a simple disposable nasal powder. This provides a significant advantage over complex systems that involve mixing liquids and powders together and then injecting the solution. Patients using the device 12 have been determined to have blood sugar levels close to normal within 30 minutes of taking powdered glucagon.

[0044] In another optional embodiment, the medicament is the intranasal AMG504-1 product (from LocemiaSolutions, Quebec, Canada), which contains 2 mg of glucagon in 20 mg of dry powder or 3 mg of glucagon in 30 mg of dry powder, depending on the dose. The nasal powder can be administered with a single-use, one-step dispensing device. The tip of the device can be inserted in one nostril, and the dose can be delivered by simply pressing an actuator 41 connected to a piston (not shown), which discharges the powder into the nostril. No patient cooperation is required because absorption occurs via the nasal mucosa. The glucagon formulation is provided in the device 12, thereby achieving efficient protection of the vitality of both the glucagon and its delivery device.

[0045] In an optional embodiment, Figure 3 and 4 As shown, the device 12 includes a body 40 disposed generally longitudinally along the device axis DA, the body having a discharge end 42 and an opposite actuator end 44. The device 12 may include a medicament reservoir 46 defined by the body 40 and may contain a medicament to be dispensed. The medicament may be dispensed via a medicament discharge port 48, which may include an opening in communication with the medicament reservoir 46.

[0046] The device 12 may optionally include an actuator 41 at the actuator end 44 for ejecting the medicament from the reservoir 46 via the discharge port 46. The actuator 41 may optionally extend beyond the actuator end 44 of the body 40. The actuator 41 may optionally move linearly from an extended position (not shown) to a depressed position (see Figure 3 and 4 ). When the actuator 41 is in the extended position, the medicament discharge port 48 can be sealed and not communicated with the medicament reservoir 46 to maintain the contained medicament in a sealed condition. The actuator 41 can be operable to discharge the medicament from the reservoir 46 immediately after axial movement from the extended position to the compressed position. During such movement, communication between the discharge port 48 and the reservoir 46 can be provided to allow the medicament to be dispensed. Additional details about the device 12 or similar devices that can be used according to optional aspects of the technology disclosed herein are disclosed in U.S. Pat. No. 10,894,133, which is incorporated herein by reference in its entirety.

[0047] The secondary package 10 may include a body or container 14 defining a cavity 16 for at least partially surrounding the device 12. The body 14 of the secondary package 10 may include a base 18 and a sidewall 20 extending upward therefrom to form the cavity 16. The end of the sidewall 20 opposite the base 18 may include a rim 22 that surrounds and / or defines an opening 24 to the cavity 16. Optionally, the body 14 may be cylindrical.

[0048] In the present optional embodiment, the body 14 of the secondary package 10 is in the form of a cylinder or bottle, and the side wall 20 may be circular and integral. However, the body or container according to the disclosed concept may be of other shapes, such as a cuboid, and thus have more than a single continuous (e.g., circular) side wall.

[0049] like Figure 3 and 4 As shown, at least a portion of cavity 16 may be spaced inwardly from the inner surface of sidewall 20 and / or spaced upwardly from the inner surface of base 18. This spacing may be the result of an object 19 placed or positioned within body 14. Object 19 may be fixed relative to body 14. Optionally, object 19 may be an active component, such as (but not limited to) a desiccant or oxygen scavenger. The size, shape, configuration, and / or position of object 19 may help prevent accidental actuation of device 12.

[0050] Optionally, the object 19 can be formed as part of a two-shot injection molding process or an overmolding process with the body 14. Optionally, the object 19 can be formed as a plug separate from the body 14 that is inserted into and optionally interlocked with the mating geometry, or optionally press-fitted into the body 14, for example.

[0051] like Figure 1-4 As shown, the secondary package 10 may include a cover or lid 26. Optionally, the lid 26 is rigid. In the current optional embodiment, the lid 26 can be in a closed position (e.g., Figure 1 , 2 and 4) with the open position (e.g. Figure 3 ), in which the cover 26 and the body 14 can optionally form a seal, such as (but not limited to) a moisture-proof seal and / or a gas-tight seal, and in which the opening 24 of the body 14 is exposed. In one embodiment, the cover 26 may include an active component.

[0052] refer to Figure 1 and 3 , the cover 26 may include an annular skirt 28 extending downward (directly or indirectly) from the top portion of the cover 26 or the periphery of the base 30. In the current optional embodiment, the base 30 is at least partially planar. Alternatively, the base 30 can be partially or completely curved or flat. Optionally, as Figure 1 , 34, the base 30 may include an upper flat surface 30a spaced apart from a lower flat surface 30b, which may be connected by a vertical or inclined surface. Therefore, in an optional embodiment, the base 30 may form a cup-shaped segment. The skirt 28 may include a first end proximate to the base 30 and an opposite second free end. The cover 26 is optionally made primarily of one or more injection moldable thermoplastic materials, the thermoplastic material including, for example, a polyolefin, such as polypropylene or polyethylene.

[0053] Optionally, a hinge 27 can connect the cover 26 to the body 14. The hinge 27 can be in the form of a living hinge, for example comprising a continuous bridge of material connecting the cover 26 to the body 14. At least a portion of the hinge 27 can be flat, rather than matching the radius of curvature of the body 14.

[0054] In an alternative embodiment, hinge 27 can be a hub-type component extending horizontally along the exterior of body 14. The hub can be held at a position spaced apart from the exterior of body 14, for example, by a pair of outwardly extending flanges. In this embodiment, cover 26 can include a partially cylindrical component that is received over the hub and pivots about the hub. Alternatively, these structures can be reversed, with cover 26 including the pivot and body 14 including the cylindrical component. In these alternative embodiments, cover 26 and body 14 can be formed separately and assembled together.

[0055] The lid 26 may optionally be resealable relative to the body 14, whether or not the secondary package 10 includes a hinge 27, or whether the lid 26 and body 14 are completely removable.

[0056] Optionally, at least a portion of device 12 may be configured to prevent movement of device 12 while within cavity 16 and / or include means for preventing movement of the device 12 that would otherwise release or administer the drug.

[0057] More specifically, in Figure 3 and 4 In an optional embodiment shown, at least one or two or more spaced apart projections 34 extend from the inner surface of the cover 26. Each projection 34 can be positioned and / or configured to abut against a non-actuator portion of the device 12. The one or more projections 34 can hold the device 12 in the cavity 16 without applying pressure to the actuator 44 when the cover 26 is in the closed position. Specifically, when the cover 16 is in the closed position, each projection 34 can extend from the cover 16 toward the bottom wall 18. In one example, each projection 34 is integrally formed of the same material as the cover 26 using a molding process. In other examples, each projection 34 can be formed separately and bonded or otherwise securely fixed to the cover 26.

[0058] Each protrusion 34 can optionally be made of a material that provides a rigid structure. In one example, the protrusions 34 are configured to maintain their relative orientation and positioning relative to the cover 26 (and, if more than one, relative to each other) and the non-actuator portion of the body 40 of the device 12 to avoid the end of the protrusion 34 from moving to an undesirable position that may cause premature actuation of the device 12. The rigid protrusion 34 can maintain its relative axial position and radial position relative to the cover 26 and the device 12.

[0059] exist Figure 2-4 , the device 12 is shown received within the body 14 of the secondary package 10. When the device 12 is properly and / or fully inserted into the body 14, at least a portion of the actuator 44 may extend upwardly beyond a plane defined by the opening 24 and extending parallel to the bottom wall 18.

[0060] Optionally, as Figure 3 and 4 As shown, the main body 18 of device 12 may include a circumferential surface or wall 45, which surrounds the actuator 44 and is coaxial with the device axis DA, and faces the direction of the back toward the bottom wall 18 when the device 12 is in the secondary packaging 10. When the lid 26 is in the closed position, each protrusion 34 can extend axially parallel to the device axis DA. Optionally, each protrusion 34 can have an end contact surface, which is positioned against the circumferential surface 45, which represents a non-actuator part, and when the device 12 is pushed to move axially in the direction of the back toward the bottom wall 18, the non-actuator part is located at the radial outside of the actuator 44 and breaks away from the actuator. In the case of rigid protrusion 34, the end contact surface maintains its relative axial position and radial position relative to the circumferential surface 45 of the lid 26 and the device 12. Each protrusion 34 may include a support rib along its radial outer surface. Other parts of the device 12 can be used as the non-actuator part contacted by the protrusion 34.

[0061] Optionally, each projection 34 is configured to prevent the device 12 from moving away from the bottom wall 18 a distance that would otherwise cause the actuator 44 to abut against the interior axial surface of the cap 26. If such contact were allowed, the device 12 could be damaged or prematurely discharge the medicament.

[0062] Each protrusion 34 is positioned and configured to interfere with movement of the device 12 within the secondary package 10 to allow movement of the device 12 in a direction away from the bottom wall 18 and toward the lid 26 by up to a predetermined amount. In some embodiments, there can be constant contact between each protrusion 34 and the peripheral surface 45 when the lid 26 is in the closed position (see Figure 3). However, in some embodiments, there may not be constant contact between each protrusion 34 and the circumferential surface 45. For example, in one optional embodiment, a first gap or space (not shown) may be provided between the end contact surface of each protrusion 34 and the circumferential surface 45. The first gap may optionally be between 0.1 mm and 1.865 mm. If an external force is applied that would cause the device 12 to move away from the bottom wall 18, the contact surface of each protrusion 34 may act as an end stop to prevent or limit such movement.

[0063] Optionally, as Figure 3 and 4 As shown, the second cover G2 may be located between the end surface of the actuator 44 and the inner surface of the base 30 of the cover 26. The second gap G2 may be at least slightly larger than the first gap G1, which prevents the actuator 44 from contacting the inner surface of the base 30.

[0064] In an optional embodiment, two spaced apart projections 34 are disposed circumferentially away from each other, and the hinge 27 is disposed circumferentially between the two projections 34 .

[0065] Optionally, a plug or lip seal may depend downwardly and / or inwardly from base 30, such as upper planar surface 30a or lower planar surface 30b of cover 26, such as described in applicant's U.S. Patent No. 11,352,177, which is incorporated herein by reference in its entirety.

[0066] For some uses, a child-resistant cover may be desirable, but may not be required for all applications. Therefore, child-resistant covers and non-child-resistant covers are carefully considered. If a child-resistant feature is provided, the child-resistant feature optionally requires applying a force in more than one single direction to the cover to remove the cover from the body. For example, the cover may require the user to press downward (first direction) before rotating the cover (second direction) in order to remove the cover from the body. Alternative child-resistant features are also carefully considered as needed.

[0067] In an optional embodiment, at least one or both of the body 14 and the cover 26 are injection molded, such as by a two-shot injection molding process. Applicants have surprisingly discovered that this also helps prevent problems with premature activation of the device 12.

[0068] Optionally, the secondary package 10, such as the cover 26 and / or the body 14 thereof, may include an object 19, an active component, or an active polymer component affixed to a portion thereof or integral therewith. For example, the active polymer component may be part of the molding process of the body 14 and / or the cover 26, such that the end user cannot visually identify the active polymer component or physically / manually remove the active polymer component from the body 14 and / or the cover 26. Optionally, the body 14 and / or the cover 26 may be formed by a two-shot or three-shot injection molding process, as described in detail below.

[0069] The active polymer component may include a base polymer entrained with one or more active agents (e.g., a mineral desiccant), and therefore may be referred to herein as a polymer entrained with an active agent or an entrained polymer. The active agent in the active polymer component may include an absorbing material, a release material, and / or an activation material. Optionally, the active polymer component is a three-phase polymer entrained with a desiccant. The active polymer component may be provided in different shapes, volumes, and / or configurations. In an exemplary embodiment, the active polymer component is in the form of a solid plug or generally flat component extending into the interior space of the cover 26.

[0070] In one embodiment, the active polymer component is a polymer entrained with a desiccant, which is an integral component made of a single piece of material. The entrained polymer, whether entrained with a desiccant or another active agent, can include a base polymer (for structure), a desiccant (or other active agent), and optionally a channeling agent. These types of active entrained polymers and methods of making and using them are disclosed in, for example, U.S. Patents Nos. 5,911,937, 6,214,255, 6,130,263, 6,080,350, 6,174,952, 6,124,006, and 6,221,446 to the applicant and U.S. Patent Publication No. 2016 / 0039955. Optionally, the entrained polymer can be in the form of a film that is loose or optionally hot-melted to a surface.

[0071] Alternatively, the desiccant may comprise loose desiccant beads or a pouch containing the desiccant beads.While the exemplary embodiments herein reflect the active polymer component being attached to, for example, the lid 26, it is contemplated that the active agent may be located at other locations and / or positions, such as on the sidewall of the body.

[0072] In the embodiment where each active component contains a desiccant, moisture absorption is required. However, in the case where moisture absorption is not required, the active component may contain an alternative active agent. For example, in another embodiment, the active component contains a material selected from the group consisting of: activated carbon, carbon black, ketjenblack and diamond powder. In another embodiment, the active agent comprises one or more layers of active components containing materials such as the following materials: absorbent microspheres, BaTiO3, SrTiO3, SiO2, Al2O3, ZnO, TiO2, MnO, CuO, Sb2O3, silicon dioxide, calcium oxide and ion exchange resin. In another embodiment, the layer containing the absorbent of the active component contains two or more types of absorbents. Select a suitable absorbent to achieve absorption of the desired vapor or gas for the desired end use (e.g., absorption of moisture, oxygen, carbon dioxide, nitrogen or other undesirable gases or vapors).

[0073] The active component (whether a desiccant, deoxidizer, release material or component, or the like, or a combination thereof) is capable of acting on, interacting with, or reacting with a selected material (e.g., moisture or oxygen). Examples of such actions or interactions may include absorption, adsorption (typically sorption), or release of a selected material. For example, each active component may be extruded or molded. Optionally, the active component may be formed into a desired shape or pattern (e.g., on a backing) via an in-line melt-adhesion thermal bonding process.

[0074] The active component may include an "active ingredient" in the base material. The active ingredient (i) may be immiscible with the base material (e.g., a polymer) and may not melt when mixed with the base polymer and the channel former and heated, i.e., may have a melting point higher than that of the base polymer or the channel former, and / or (ii) may act on, interact with, or react with a selected material. The term "active ingredient" may include, but is not limited to, a material that absorbs, adsorbs, or releases a selected material. According to the technology of the present disclosure, the active ingredient may be in particulate form, such as a mineral (e.g., in the case of a desiccant, a molecular sieve or silica gel), but the technology of the present disclosure should not be considered to be limited to particulate active agents. For example, in some embodiments, the deoxygenation formulation may be made of a resin that acts as an active agent or a component of an active agent.

[0075] As used herein, the term "base material" is a component (preferably a polymer) of the entrained active material other than the active agent that provides the structure of the entrained material.

[0076] As used herein, the term "base polymer" is a polymer having a gas permeability of the selected material that is significantly lower than, lower than, or substantially equivalent to the gas permeability of the channeling agent. By way of example, in an embodiment where the selected material is moist and the active ingredient is a water-absorbing desiccant, this permeability will be a water vapor permeability. The main function of the base polymer is to provide a structure for entrained polymers. Suitable base polymers may include thermoplastic polymers, such as polyolefins (e.g., polypropylene and polyethylene), polyisoprene, polybutadiene, polybutylene, polysiloxane, polycarbonate, polyamide, ethylene-vinyl acetate copolymer, ethylene-methacrylate copolymer, poly(vinyl chloride), polystyrene, polyester, polyanhydride, polyacrylonitrile, polysulfone, polyacrylate, acrylic acid, polyurethane, and polyacetal, or copolymers or mixtures thereof.

[0077] With reference to this comparison of the water vapor permeability of the base polymer and the channeling agent, in one embodiment, the water vapor permeability of the channeling agent is at least twice the water vapor permeability of the base polymer. In another embodiment, the channeling agent has a water vapor permeability of at least five times the water vapor permeability of the base polymer. In another embodiment, the channeling agent has a water vapor permeability of at least ten times the water vapor permeability of the base polymer. In yet another embodiment, the channeling agent has a water vapor permeability of at least twenty times the water vapor permeability of the base polymer. In yet another embodiment, the channeling agent has a water vapor permeability of at least fifty times the water vapor permeability of the base polymer. In yet another embodiment, the channeling agent has a water vapor permeability of at least one hundred times the water vapor permeability of the base polymer.

[0078] As used herein, the term "channeling agent" or "channeling agent" is defined as a material that is immiscible with a base polymer and has an affinity for transporting gas-phase materials at a faster rate than the base polymer. Optionally, the channeling agent is capable of forming channels through the entrained polymer when formed by mixing the channeling agent with the base polymer. Optionally, such channels are capable of transporting a selected material through the entrained polymer at a faster rate than the base polymer alone.

[0079] As used herein, the term "channel" or "interconnected channels" is defined as passages formed by a channeling agent that penetrate a base polymer and may be interconnected with each other.

[0080] As used herein, the term "entrained polymer" is defined as a monolithic material formed by at least a base polymer with an active agent and optionally also a channeling agent entrained or distributed therein. Entrained polymers thus include two-phase polymers and three-phase polymers. "Mineral-loaded polymers" are a type of entrained polymer in which the active agent is in the form of a mineral, for example, mineral particles such as molecular sieves or silica gel. The term "entrained material" is used herein to indicate a monolithic material comprising an active agent entrained in a base material, wherein the base material may or may not be polymeric.

[0081] As used herein, the term "monolithic," "monolithic structure," or "monolithic composition" is defined as a composition or material that is not composed of two or more discrete macroscopic layers or parts. Accordingly, a "monolithic composition" does not include a multilayer composite.

[0082] As used herein, the term "phase" is defined as a portion or component of a monolithic structure or composition uniformly distributed therein to give the structure or composition its monolithic character.

[0083] As used herein, the term "selected material" is defined as a material that acts on, acts through, or interacts or reacts with an active agent and is capable of being transported through the channels of the entrained polymer. For example, in embodiments where a desiccant is used as the active agent, the selected material may be moisture or a gas that can be absorbed by the desiccant. In embodiments where a releasing material is used as the active agent, the selected material may be an agent released by the releasing material, such as moisture, a fragrance, or an antimicrobial agent (e.g., chlorine dioxide). In embodiments where an adsorbent material is used as the active ingredient, the selected material may be certain volatile organic compounds, and the adsorbent material may be activated carbon.

[0084] As used herein, the term "three-phase" is defined as a monolithic composition or structure comprising three or more phases. An example of a three-phase composition according to the technology disclosed herein would be an entrained polymer formed from a base polymer, an active agent, and a channeling agent. Optionally, the three-phase composition or structure may include additional phases, such as a colorant.

[0085] The entrained polymer can be a two-phase formulation (i.e., including a base polymer and an active ingredient without a channeling agent) or a three-phase formulation (i.e., including a base polymer, an active agent, and a channeling agent). Entrained polymers are described, for example, in U.S. Pat. Nos. 5,911,937, 6,080,350, 6,124,006, 6,130,263, 6,194,079, 6,214,255, 6,486,231, 7,005,459, and U.S. Patent Publication No. 2016 / 0039955.

[0086] The entrained material or polymer comprises a base material (e.g., a polymer) for providing a structure, optionally a channel former and an active agent. The channel former forms microscopic interconnected channels through the entrained polymer. At least some of the active ingredients are contained in these channels so that the channels communicate between the active ingredient and the outside of the entrained polymer via microscopic channel openings formed at the outer surface of the entrained polymer. The active ingredient can be, for example, any of a variety of absorbing, adsorbing or releasing materials, as described in further detail below. Although channel forming components are preferred, the technology of the present disclosure broadly includes entrained materials, such as two-phase polymers, that optionally do not include channel formers.

[0087] In any embodiment, suitable channel formers may include polyglycols (e.g., polyethylene glycol (PEG)), ethylene vinyl alcohol (EVOH), polyvinyl alcohol (PVOH), glycerol polyamines, polyurethanes, and polycarboxylic acids including polyacrylic acid or polymethacrylic acid. Alternatively, the channel former may be, for example, a water-insoluble polymer, such as propylene oxide polymer-monobutyl ether, such as Polyglykol B01 / 240 produced by CLARIANT. In other embodiments, the channel former may be propylene oxide polymer-monobutyl ether, such as Polyglykol B01 / 20 produced by CLARIANT; propylene oxide polymer, such as Polyglykol D01 / 240 produced by CLARIANT; ethylene vinyl acetate; nylon 6; nylon 66; or any combination thereof.

[0088] Suitable active ingredients according to the technology of the present disclosure include absorbent materials, such as desiccating compounds. If the active agent is a desiccant, any suitable desiccant for a given application can be used. Generally, for many applications, physical absorption desiccants are preferred. These can include molecular sieves, silica gel, clays and starches. Alternatively, the desiccant can be a chemical compound that forms crystals containing water, or a compound that reacts with water to form a new compound.

[0089] Optionally, in any embodiment, the active agent can be an oxygen scavenger, such as an oxygen scavenging resin formulation.

[0090] In one optional embodiment, the active agent is or comprises a 3A molecular sieve. The pore diameter or molecular sieve is usually measured in angstroms (A), and a 3A molecular sieve refers to a pore size of 3 angstroms. The applicant unexpectedly found that the use of a 3A molecular sieve helps to reduce pressure buildup during the required testing of the secondary package 10, especially compared to and / or replacing a 4A molecular sieve. By reducing pressure buildup, the secondary package 10 is less likely to be accidentally opened with the risk of contaminating and / or prematurely activating the device 12. Additional discussion of the benefits of a 3A molecular sieve is discussed in the applicant's WO 2022 / 032278, which is incorporated herein by reference.

[0091] Optionally, the mass of object 19 is exactly or approximately 14.6 grams, which contains exactly or approximately 9.2 grams of 3A molecular sieve. Optionally, the mass of object 19 can be 13-16 grams. Optionally, the mass of 3A molecular sieve can be 8-10 grams.

[0092] Applicants believe that the smaller angstrom size of 3A molecular sieves reduces outgassing compared to 4A molecular sieves, thereby generating less outgassing pressure and / or reducing the pressure within the secondary package 10. This is particularly true during testing that requires the secondary package 10 to be maintained in a high temperature (e.g., 50° C.) or low temperature environment for extended periods of time (e.g., 96 hours). Prior to this unexpected discovery, 3A molecular sieves were used in situations where additional absorption capacity was required.

[0093] Figure 5 The results of the comparative test between 3A molecular sieve desiccant and 4A molecular sieve desiccant are shown, wherein the graph of the volume of gas released relative to time is drawn. The test is carried out by exposing each sample of 3A and 4A molecular sieve to 50°C temperature for 184 hours. Each 14 grams of 3A and 4A molecular sieve samples are placed in a sealed tube, each of which is connected to a graduated cylinder placed in water. During the experiment, all gases released by the samples placed in the sealed tubes are directly stored in the graduated cylinder. In this way, the volume of gas released can be observed.

[0094] like Figure 5 As shown, after 184 hours of exposure at 50° C., the 3A-based formulation sample (14 grams of compound) was observed to release about 7.2 mL of gas. For the 4A-based formulation, the same amount of compound released 46 mL of gas, which is about 7 times that of the 3A-based formulation. These results are consistent with the pressure monitoring tests performed, as discussed immediately below.

[0095] Figure 6Results of a pressure monitoring test of a secondary package 10 demonstrating the disclosed technology. The goal of this test was to determine the differential overpressure in the headspace of a secondary package 10 using a 3A molecular sieve desiccant versus a package using a 4A molecular sieve desiccant when both were exposed to a temperature of 50°C for 7 days.

[0096] Use one STAR ODDI for each of the two secondary packages (i.e., vials) TM Data logger. Each vial was exposed to 50°C temperature (uncontrolled RH) for 7 days. After 7 days, data from the data logger was extracted and analyzed. Pressure was measured every 15 minutes over the 7 day period.

[0097] It was observed that when both 3A and 4A based desiccant vials were exposed to a temperature of 50°C, the pressure inside the vial initially increased due to gas expansion. This pressure increase continued for several hours until the pressure inside the vial reached approximately 100 mbar. During this stage, no differences between the two desiccant formulations were observed.

[0098] However, after approximately 5 hours of exposure at 50° C., significant differences were observed between the vials using 3A molecular sieves and 4A molecular sieves. Specifically, after 7 days, the pressure within the vials made of or using 4A molecular sieves increased to approximately 200 mbar, while during this time period, the pressure within the vials made of or using 3A molecular sieves dropped from a peak of 100 mbar to approximately 50 mbar.

[0099] It has been determined that when exposed to a temperature of 50°C, the 4A molecular sieve releases a significant amount of gas in the head space of the vial. Considering the airtightness of the vial, this results in an overpressure of 200 mbar in the vial. In contrast, it has been determined that the 3A molecular sieve does not release a significant amount of gas, and the overpressure in the vial is very low after 7 days. These findings are significant in at least two aspects. First, the final pressure measurement results under the stated conditions show that the internal pressure of the package with the 3A molecular sieve is significantly lower than the internal pressure of the package with the 4A molecular sieve of equivalent mass. Second, not only does the 3A molecular sieve produce a significantly lower final pressure measurement result, but also after initially reaching a peak, the package with the 3A molecular sieve experiences a pressure drop, while the pressure of the package with the 4A molecular sieve continues to increase. These findings are noteworthy. In fact, compared with the package using the 4A molecular sieve of equivalent mass, the probability of accidentally opening the package using the 3A molecular sieve is significantly lower.

[0100] Figure 7-12 Another embodiment of the technology of the present disclosure is presented. Figure 7-12 Examples and Figure 1-4 Similar or identical structures between the embodiments are Figure 7-12 Medium throughput ratio Figure 1-4 The reference numerals are distinguished by the value of one hundred (100). Figure 1-4 Examples and Figure 7-12 Features of one embodiment may be omitted or added to other embodiments.

[0101] Optionally, the maximum height of the secondary package 110 is 81.17 mm, or optionally 79 mm to 83 mm. Optionally, the maximum diameter of the body 114 of the secondary package 110 is 34.98 mm, or optionally 33 mm to 36 mm. Optionally, the maximum width of the secondary package 110 (i.e., the lid 126 plus the hinge 127) is 43.97 mm, or optionally 42 mm to 45 mm. Optionally, the internal volume of the secondary package is 36,651 mm 3 , optionally 30,000 to 40,000 mm 3 , optionally 34,000 to 38,000 mm 3 .

[0102] like Figure 7-9A As shown, the lid 126 may optionally be formed from a semi-rigid material with the hinge 127 molded directly to the body 114 of the secondary package 110. One or more of these components may optionally be formed from polypropylene.

[0103] refer to Figure 7 and 8 , object 119 can optionally include a plurality of circumferentially spaced fins or ribs 119a, each fin or rib extending inwardly from main body 114.Each fin 119a can be tapered, so that its width as measured radially from the geometric center of main body 114 toward its outer wall is smaller at or near the top of fin 119a than at or near the bottom of fin 119a.This shape or configuration can promote device (not shown) to be inserted into secondary packaging 110 and / or promote to prevent accidental actuation of device.In addition, this shape increases the surface area of ​​object 119, which may be useful when object is an active polymer.In this way, object 119 has more exposed surface areas, and the exposed surface areas can be used to provide desired activity, such as hygroscopic.In identical or different embodiments, the thickness of each fin 119a as measured perpendicular to width can be the same on the whole height of fin 119a.Alternatively or in addition, object 119 can be formed in the cylinder of at least a portion of receiving device therein.

[0104] like Figure 7-9BAs shown, the cover 126 can optionally include a tab 156 extending laterally outward therefrom. The tab 156 can be sized, shaped, and / or configured to be engaged by a user, such as a user's thumb, to help move the cover 126 between the open position and the closed position. The tab 156 can optionally be positioned diametrically opposite the hinge 127.

[0105] refer to Figure 10-12 , the cover 126 and / or the body 114 may be formed with a locking feature. The locking feature may be configured to maintain the cover 126 in a closed position relative to the body even in the presence of internal pressure within the cavity of the body 114 in the absence of intended separation or relative movement of the two components. Any such locking mechanism may be used that provides sufficient security to maintain the components in a locked state while also allowing for reasonable release of the locking mechanism when desired.

[0106] Optionally, the locking feature may include at least one rib 150 designed to prevent unintentional opening and / or pre-opening of the secondary package 110. The center of the locking feature may be positioned relative to the hinge 127, i.e., approximately 180° from the center of the hinge 127. Such a configuration will help maximize the closing effect of the locking feature and help ensure consistent opening and closing forces of the secondary package 110. Fig.11 As shown, each rib 150 may be located below the rim 122 and / or lip 123 of the body 114 .

[0107] In an optional embodiment, two spaced apart ribs 150 may extend radially outward from the sidewall of the body 114, and the cover 126 may include two corresponding spaced apart openings 152 in the latch 151 attached to and depending from the lower surface of the tab 156 of the cover 126. Each opening 152 may be sized, shaped, and / or configured to receive at least a portion of one of the ribs 150 when the cover 126 is in the closed position (see Fig.10 ).

[0108] In operation of an optional embodiment, a user can apply an axial force (e.g., an upward force) to the underside of tab 156 to cause tab 156 to at least slightly pivot (e.g., upward) due to the flexibility of tab 156, thereby moving latch 151 in a manner (e.g., outward) such that each opening 152 is removed and / or separated from the corresponding rib 150, and latch 151 moves away from the corresponding rib 150 to allow cover 126 to move from a closed position to an open position.

[0109] In one optional embodiment, to disengage the locking feature, all that is required is the act of holding the body 114 (eg, by hand) and applying an upward force to the underside of the tab 156 .

[0110] As slight variations, there may be a single rib with one or more corresponding openings or more than two ribs.An additional alternative to the locking feature in accordance with optional aspects of the disclosed concept is any version of the attachment mechanism disclosed in Applicant's US Pat. No. 11,352,177 disclosed above.

[0111] Optionally, in any embodiment, the locking feature can be implemented in combination with an annular skirt 28 extending downwardly from the periphery of the base of the cover 26, 126. In such embodiments, the annular skirt or a portion thereof can act as the depending latch described above.

[0112] Optionally, the technology of the present disclosure may include a rim of the body having an outer surface that includes an undercut relative to the central axis of the body. The undercut may have a surface that mates with a corresponding surface of the skirt in a snap-fit ​​closure configuration when the lid is closed. The snap-fit ​​closure configuration can inhibit accidental opening of the lid and can form a moisture-proof seal between the body and the lid. An example of such an arrangement is shown and described in Applicant's U.S. Patent No. 11,192,698, which is incorporated herein by reference in its entirety.

[0113] Optionally, a snap fit closure and moisture proof seal between the body and the lid can be combined with a locking feature to further ensure that the lid is prevented from accidentally opening relative to the body due to, for example, pressure buildup within the package. This combination of snap fit and seal / closure can be located between the skirt and the body, the locking feature, or both.

[0114] The following exemplary embodiments further describe optional aspects of the technology of the present disclosure and are part of this detailed description. These exemplary embodiments are stated in a format generally similar to the claims (each with a number followed by a capital letter), but they are not technically claims of the present application. The following exemplary embodiments are referenced as "embodiments" rather than "claims" in a subordinate relationship to each other.

[0115] 1A. A combination comprising:

[0116] Devices for administering medication; and

[0117] A secondary package is configured to surround the device, the secondary package being configured to resist or prevent accidental opening of the device, the secondary package comprising a body defining a cavity for at least partially surrounding the device for administering the drug therein when the device is located within the cavity.

[0118] 2A. The combination of Embodiment 1A, wherein the device is a nasal drug delivery device.

[0119] 3A. A combination according to Example 2A, wherein the nasal drug delivery device can be reconfigured between an inactivated configuration and an activated configuration, wherein the inactivated configuration the nasal drug delivery device does not release or administer the drug, and wherein the activated configuration the nasal drug delivery device does release or administer the drug.

[0120] 1B. A secondary package configured to prevent accidental actuation of an inhaler, the secondary package comprising a body defining a cavity for at least partially surrounding the inhaler, the body containing means for preventing movement of the inhaler that would otherwise release or administer medicament from the inhaler.

[0121] 1C. A secondary package configured to hold a device for administering a medicament, the secondary package comprising:

[0122] a body defining a cavity for at least partially surrounding said device for administering said medicament; and

[0123] a cover movable relative to the body between a closed position and an open position,

[0124] At least one of the body and the cover comprises an active polymer component formed from a base polymer entrained with a 3A molecular sieve.

[0125] 2C. The secondary package of Embodiment 1C wherein the body has a base and sidewalls extending upward from the base.

[0126] 3C. The secondary package of Embodiment 2C wherein an end of the side wall opposite the base includes a rim defining an opening to the cavity.

[0127] 4C. The secondary package of Embodiment 3C wherein the cover is pivotally attached to the body between a closed position in which the cover forms a moisture-tight seal with the body and an open position in which the opening of the body is exposed.

[0128] 5C. The secondary package of Embodiment 4C wherein the cover comprises an annular skirt extending downwardly from a periphery of a base of the cover, the skirt having a first end proximate the base and an opposing second free end.

[0129] 6C. The secondary packaging of Embodiment 4C or 5C wherein the cover comprises a tamper-evident feature in or on the cover.

[0130] 7C. The secondary package of Embodiment 4C or 5C wherein the cover includes a latch in or on the cover to maintain the cover in the closed position relative to the body.

[0131] 8C. The secondary package of Embodiment 3C wherein the rim extends laterally outward from the sidewall and parallel to the base of the body.

[0132] 9C. The secondary package of any one of Embodiments 1C-8C, wherein the inner surface of the base of the lid comprises a step configured to have two spaced-apart surfaces, each surface extending parallel to the base of the body when the lid is in the closed position.

[0133] 10C. The secondary packaging of Embodiment 9C, wherein at least one of the two spaced-apart surfaces is configured to contact at least a portion of the device to prevent reconfiguration of the device from the inactivated position to the activated position. 10C.

[0134] 11C. The secondary package of any of Embodiments 1C-10C wherein the base of the lid is planar or curved.

[0135] 1D. A secondary package configured to hold a device for administering a medicament, the secondary package comprising:

[0136] a body defining a cavity for at least partially surrounding said device for administering said medicament; and

[0137] a cover movable between a closed position and an open position relative to the body, the cover including a latch in or on the cover to maintain the cover in the closed position relative to the body,

[0138] wherein at least one of the body and the cover comprises an active polymer component formed from a base polymer entrained with a 3A molecular sieve, and

[0139] At least one of the body and the cover is formed by a two-shot injection molding process.

[0140] 2D. The secondary packaging of Embodiment ID wherein the body and the cap combine to form a vial.

[0141] 1E. A combination comprising:

[0142] Nasal drug delivery systems; and

[0143] A secondary package configured to hold the nasal medication delivery system, the secondary package being in the form of a vial, comprising:

[0144] a body defining a cavity for at least partially surrounding said device for administering said medicament; and

[0145] a cover movable between a closed position and an open position relative to the body, the cover including a latch in or on the cover to maintain the cover in the closed position relative to the body,

[0146] wherein at least one of the body and the cover comprises an active polymer component formed from a base polymer entrained with a 3A molecular sieve, and

[0147] At least one of the body and the cover is formed by a two-shot injection molding process.

[0148] 1F. A method of manufacturing a secondary package configured to hold a device for administering a drug, the method comprising:

[0149] The main body and the cover of the secondary package are subjected to two-shot injection molding,

[0150] At least one of the body and the cover comprises an active polymer component formed from a base polymer entrained with a 3A molecular sieve.

[0151] 1G. A secondary package configured to hold a device for administering a medicament, the secondary package comprising:

[0152] a body defining a cavity for at least partially surrounding said device for administering said drug;

[0153] a cover attached to at least a portion of the body by a hinge, the cover being movable relative to the body between a closed position and an open position, the body and cover together defining an interior compartment for housing the device when the cover is in the closed position; and

[0154] 3A molecular sieve, which is located in the inner compartment.

[0155] 2G. The secondary packaging of Embodiment 1G, wherein the 3A molecular sieve is part of an active polymer assembly further comprising a base polymer and an optional channeling agent.

[0156] 1H. A secondary package configured to hold a device for administering a medicament, the secondary package comprising:

[0157] a body defining a cavity for at least partially surrounding said device for administering said medicament; and

[0158] a cover attached to at least a portion of the body by a hinge, the cover being movable relative to the body between a closed position and an open position,

[0159] At least one of the body and the cover comprises or is attached to an active polymer component including a 3A molecular sieve.

[0160] 2H. The secondary package of embodiment 1H, wherein the 3A molecular sieve does not form additional pressure within the body after the lid is in the closed position for 7 days.

[0161] 3H. A secondary package according to Example 1H, wherein the 3A molecular sieve produces less outgassing than the 4A molecular sieve after the lid is in the closed position for 7 days, so that the 3A molecular sieve does not form additional pressure in the body when the lid is in the closed position.

[0162] 4H. The secondary package of any of Embodiments 1H-3H, wherein the body and the lid are placed in an environment of at least 40°C.

[0163] 5H. The secondary package of any of Embodiments 1H-3H, wherein the body and the lid are placed in an environment of at least 50°C.

[0164] 6H. The secondary package of embodiment 1H, wherein after 7 days, when the lid is in the closed position, the pressure within the body decreases.

[0165] 7H. The secondary package of embodiment 6H, wherein after 6 days, when the lid is in the closed position, the pressure within the body is less than 50 mbar.

[0166] 8H. The secondary package of any of Embodiments 1H-7H, wherein the body has a base and sidewalls extending upward from the base.

[0167] 9H. The secondary package of Embodiment 8H wherein an end of the side wall opposite the base includes a rim defining an opening to the cavity.

[0168] 10H. The secondary package of embodiment 9H wherein the cover comprises an annular skirt extending downwardly from a periphery of a base of the cover, the skirt having a first end proximate the base and an opposing second free end.

[0169] 11H. The secondary packaging of Embodiment 9H or 10H, wherein the cover comprises a tamper-evident feature in or on the cover.

[0170] 12H. The secondary package of Embodiment 9H or 10H, wherein the lid includes a latch in or on the lid to maintain the lid in the closed position relative to the body.

[0171] 13H. The secondary package of Embodiment 9H wherein the rim extends laterally outward from the sidewall and parallel to the base of the body.

[0172] 14H. A secondary package according to any of embodiments 1H-13H, wherein the inner surface of the base of the lid includes a step, the step being configured to have two spaced-apart surfaces, each surface extending parallel to the base of the body when the lid is in the closed position.

[0173] 15H. The secondary packaging of Embodiment 14H wherein at least one of the two spaced-apart surfaces is configured to contact at least a portion of the device to prevent reconfiguration of the device from the inactivated position to the activated position.

[0174] 16H. The secondary package of any of Embodiments 1H-15H wherein the base of the lid is planar or curved.

[0175] 17H. The secondary packaging of any of Embodiments 1H-16H, wherein the entrained polymer composition comprises a base polymer and an optional channeling agent.

[0176] 18H. The secondary package of any of Embodiments 1H-17H wherein at least one of the body and the lid is formed by a two-shot injection molding process.

[0177] 19H. The secondary packaging of any of Embodiments 1H-18H, wherein the body and lid combine to form a vial.

[0178] 1I. A combination comprising:

[0179] Nasal drug delivery systems; and

[0180] A secondary package configured to hold the nasal medication delivery system, the secondary package being in the form of a vial, comprising:

[0181] a body defining a cavity for at least partially surrounding said device for administering said medicament; and

[0182] a cover movable between a closed position and an open position relative to the body, the cover including a latch in or on the cover to maintain the cover in the closed position relative to the body,

[0183] wherein at least one of the body and the cover comprises an active polymer component comprising a 3A molecular sieve, and

[0184] At least one of the body and the cover is formed by a two-shot injection molding process.

[0185] 1J. A method of manufacturing a secondary package configured to hold a device for administering a medicament, the method comprising:

[0186] The main body and the cover of the secondary package are subjected to two-shot injection molding,

[0187] An active polymer assembly including 3A molecular sieve is inserted into one of the body and the cover.

[0188] 1K. A method of preventing accidental opening of a container due to pressure buildup within the container, optionally when the container is in an environment having a temperature of 50 degrees Celsius or higher, the method comprising:

[0189] A reactive polymer reagent comprising 3A molecular sieves is provided to the container.

[0190] 2K. The method of embodiment 1K, further comprising:

[0191] maintaining the cover of the body of the container in a closed position that protects the container from moisture for at least 7 days,

[0192] wherein the pressure within the head space of the container decreases after said 7 days, optionally to below 100 mbar.

[0193] Although the technology of the present disclosure has been described in detail with reference to its specific examples, it is obvious to those skilled in the art that various changes and modifications may be made therein without departing from its spirit and scope. Therefore, it should be understood that the technology of the present disclosure is not limited to the specific embodiments disclosed, but is intended to cover modifications within the spirit and scope of the technology of the present disclosure.

Claims

1. A secondary package configured to hold a device for administering a medicament, the secondary package comprising: a body defining a cavity for at least partially surrounding said device for administering said drug; a cover attached to at least a portion of the body by a hinge, the cover being movable relative to the body between a closed position and an open position, the body and cover together defining an interior compartment for housing the device when the cover is in the closed position; as well as An active polymer component is positioned within the interior compartment, the active polymer component being configured to receive at least a portion of the device therein, the active polymer component comprising a mixture of 3A molecular sieve, a base polymer, and an optional channeling agent. 2 . The secondary package of claim 1 , wherein the body is cylindrical and includes a base and a sidewall extending upwardly from the base.

3. The secondary package of claim 2, wherein an end of the side wall opposite the base includes a rim defining an opening to the cavity.

4. The secondary package of claim 3, wherein the cover has an annular skirt extending downwardly from a periphery of a base of the cover, the skirt having a first end proximate the base and an opposing second free end.

5. A secondary package according to claim 4, wherein the rim has an outer surface, the outer surface includes an undercut relative to the central axis of the body, the undercut has a surface that cooperates with a corresponding surface of the skirt in a snap-fit ​​closure configuration when the lid is closed, wherein the snap-fit ​​closure configuration inhibits accidental opening of the lid and forms a moisture-proof seal between the body and the lid.

6. The secondary package of any one of claims 2 to 5, wherein the cover further comprises a latch that engages a mating geometry of the cover in the closed position to retain the cover in the closed position and thereby inhibit accidental opening of the cover.

7. The secondary packaging of claim 6, wherein the latch includes at least one opening and the body includes at least one rib configured to mate with the at least one opening in a snap-fit ​​configuration.

8. The secondary package of claim 6, further comprising a plug or lip seal depending from a base of the lid, the plug or lip seal being configured to engage an inner surface of the sidewall to form a moisture resistant seal between the lid and the body.

9. The secondary package of any one of claims 5 to 8, further comprising a resilient seal on an underside of the lid, the resilient seal being configured to engage at least a portion of the body when the lid is in the closed position to form a moisture resistant seal between the lid and the body.

10. A secondary package according to any one of claims 2 to 9, wherein the active polymer component is attached to or integral with the side wall of the body, optionally by a multi-shot injection molding process, and the active polymer component includes a central axial cavity configured to receive and surround a portion of the device.

11. The secondary packaging of claim 10, the central cavity terminating in an annular ledge configured to provide a seating surface for an annular flange of a body of the device.

12. The secondary packaging of any preceding claim, wherein the volume of the internal compartment is 15 mL to 120 mL, optionally 15 mL to 100 mL, optionally 15 mL to 80 mL, optionally 15 mL to 60 mL, optionally 15 mL to 50 mL, optionally 20 mL to 40 mL.

13. A secondary package according to any preceding claim, wherein the 3A molecular sieve is present in the active polymer component at 30% to 80%, optionally 30% to 75%, optionally 30% to 70%, optionally 35% to 70%, optionally 40% to 70%, optionally 45% to 65%, optionally 50% to 60% by weight of the mixture.

14. A secondary package according to any preceding claim, wherein the secondary package is moisture resistant when the lid is in the closed position, and wherein at a storage temperature of 50°C, the active polymer component generates an initial gas release, causing pressure to accumulate in the internal compartment and reach a peak pressure, followed by a decrease in pressure in the internal compartment while the lid remains in the closed position.

15. The secondary packaging of claim 14, wherein the final pressure measured after seven days under these conditions is less than the peak pressure, optionally from 40% to 75% of the peak pressure, optionally from 40% to 70% of the peak pressure, optionally from 40% to 60% of the peak pressure, optionally from 45% to 55% of the peak pressure, optionally about 50% of the peak pressure.

16. The secondary packaging of claim 14 or 15, wherein the peak pressure is reached within one day, optionally within 18 hours, optionally within 12 hours, optionally between 2 and 10 hours, optionally between 3 and 8 hours, optionally within about 5 hours after the lid is placed in the closed position.

17. A secondary package according to any one of claims 15 or 16, wherein the peak pressure is from 80 mbar to 120 mbar and the final pressure is from 40 mbar to 60 mbar.

18. A secondary package according to any one of claims 14 to 17, wherein the pressure built up within the interior compartment is insufficient to cause the lid to open accidentally.

19. A secondary package according to any preceding claim, wherein the lid comprises a base, at least a portion of which is arched to project vertically above the rim when the lid is in the closed position and thereby form a recess in the lid configured to accommodate a portion of the device.

20. A medication delivery system comprising a secondary package according to any preceding claim and a drug delivery device stored in the secondary package.

21. A drug delivery system according to claim 20, wherein the drug delivery device includes a body having a discharge end defining a drug discharge port and an opposite actuator end, the drug delivery device includes a drug reservoir in which the drug is stored, and the drug delivery device further includes an actuator for ejecting the drug from the reservoir via the discharge port, the actuator extending out of the actuator end of the body, the actuator being capable of linearly moving from an extended position to a compressed position, when the actuator is in the extended position, the discharge port is sealed, and when the actuator is in the compressed position, the discharge port is open, and the actuator is capable of being operated to discharge the drug from the reservoir immediately after the actuator is axially moved from the extended position to the compressed position.

22. The drug delivery system of claim 21, wherein the drug delivery device is configured for intranasal administration and the drug is in the form of a liquid, an aerosol, a gel or a powder when administered.

23. The drug delivery system of claim 22, wherein the drug is a formulation comprising one or more of the following active pharmaceutical ingredients: naloxone, ketamine, midazolam, fentanyl, lorazepam, nalmefene, epinephrine, apomorphine, cetrorelix, loxapine, eletriptan, ketorolac, glucagon, and olanzapine.

24. A method of providing storage stability to a drug contained in a drug delivery device stored in a secondary package, the secondary package having a lid and a body, the lid being pivotable relative to the body about a hinge, the storage stability being maintained by providing an environment having low or no relative humidity and by ensuring that the lid is not accidentally opened while the drug delivery device is stored in the secondary package, the method comprising: When the cover is in a closed position relative to the body, an active polymer assembly is positioned within an interior compartment formed by the cover and the body, the active polymer assembly comprising a base polymer and a 3A molecular sieve.

25. The method of claim 24, wherein the active polymer component further comprises a channeling agent.

26. The method of claim 24, further comprising: inserting the drug delivery device into the secondary package; as well as moving the cover from an open position to a closed position relative to the body, thereby enclosing the drug delivery device within the secondary package, The secondary packaging prevents accidental actuation of the drug delivery device and creates a low relative humidity or no relative humidity environment in the closed cavity of the secondary packaging.

27. The method of claim 26, further comprising: moving the cover from the closed position relative to the body; removing the drug delivery device from the secondary packaging; as well as The drug within the drug delivery device is administered to a patient.

28. A method of treating a patient in need of an intranasally administered medication, the method comprising: A secondary package according to any one of claims 1 to 19, wherein the secondary package stores a drug delivery device therein, the drug delivery device comprising a body having a discharge end defining a drug discharge port and an opposing actuator end, the drug delivery device comprising a drug reservoir having a drug stored therein, the drug delivery device further comprising an actuator for ejecting the drug from the reservoir via the discharge port, the actuator extending out of the actuator end of the body, the actuator being linearly movable from an extended position to a compressed position, the discharge port being sealed when the actuator is in the extended position, and the discharge port being open when the actuator is in the compressed position, the actuator being operable to discharge the drug from the reservoir immediately after the actuator is axially moved from the extended position to the compressed position; removing the drug delivery device from the secondary packaging; inserting the discharge tip into a nostril of the patient; as well as The drug delivery device is actuated to administer the drug intranasally to the patient.

29. The method of claim 28, wherein the storage stability of the drug is maintained by: providing an environment with low or no relative humidity within the secondary package when the secondary package is in the closed position by using a 3A molecular sieve desiccant and the moisture barrier properties of the secondary package; and This ensures that the cover cannot be accidentally opened while the drug delivery device is stored in the secondary packaging.

30. The method of claim 28 or 29, wherein the drug is a formulation comprising one or more of the following active pharmaceutical ingredients: naloxone, ketamine, midazolam, fentanyl, lorazepam, nalmefene, epinephrine, apomorphine, cetrorelix, loxapine, eletriptan, ketorolac, glucagon, and olanzapine.

Citation Information

Cited By

  • Drug use monitoring device and system and drug use monitoring method

    CN121197596A

  • Medication monitoring device, system, and medication monitoring method

    CN121197596B